“I would argue that for nearly every common disease, there are multiple forms of the disease that have been amalgamated into one definition that all result in the same end pathology. Whether that end pathology is heart disease, Alzheimer’s disease, liver disease, lung disease, GI illness, renal disease, et cetera. Now, we know it to be the case clinically, that you can have 100 people with heart disease or lung disease or brain disease, and that some individuals are going to have very different clinical responses and progressions relative to other individuals. So to argue they all have the identical disease state makes no sense. It’s just the way we can simplify a very complex problem and make sense of it in a way to categorize and understand disease. But to not understand that there are multiple forms of a disease is really where we get led astray.”
Listen to hear Dr. Mo Jain’s full conversation with the Futurati podcast team, including hosts Trent Fowler and Thomas Frey, as they talk through the challenges still limiting the advancement of personalized medicine, and how small molecule biomarkers can be used to not only better understand disease processes and subset individuals by their unique disease biology, but to align the right treatment that effectively targets the pathways involved in their disease.
Listen above or by searching “Futurati” on your favorite podcast platform!

Futurati Podcast: Biomarkers and personalized medicine
“I would argue that for nearly every common disease, there are multiple forms of the disease that have been amalgamated into one definition that all result in the same end pathology. Whether that end pathology is heart disease, Alzheimer’s disease, liver disease, lung disease, GI illness, renal disease, et cetera. Read More

VibeCast Podcast: Are Biomarkers the Future?
“Diagnostics have evolved tremendously. You could argue that the greatest benefit in human survival has come over the last 50 years because we’ve gotten much better at diagnosing disease at an earlier stage. But there’s still quite a ways to go before we’re perfect in this. One of the real… Read More

“Beyond Biotech” Podcast: A look at metabolite biomarkers with Sapient
“My hope is that in the very near future, in the next decade, an individual would go to a doctor’s office once a year and instead of measuring 12 things in a blood sample, we are going to measure several hundred things in that blood sample, and we are going… Read More

“Lab to Launch” Podcast: Enabling the next generation of biomarker discovery with Dr. Mo Jain
If you look at the data, the best drugs work in only 50% of people. Sapient’s Founder and CEO, Dr. Mo Jain, sits down with Kelly Stanton, Director of Quality at Qualio, to explain this fundamental challenge and how it ultimately led to the creation of Sapient. Read More

SLAS New Matter Podcast: A Conversation on Small Molecule Biomarkers with Dr. Mo Jain
SLAS Scientific Manager Hannah Rosen, PhD is joined by Sapient Founder and CEO Mo Jain, MD, PhD, for an insightful discussion on small molecule biomarkers. Did you know that methods of utilizing small molecule biomarkers for diagnostics date all the way back to ancient Greece? Listen to hear how, along with the many… Read More